Your browser doesn't support javascript.
loading
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Drusano, G L; Okusanya, Olanrewaju O; Okusanya, Adedoyin; Van Scoy, Brian; Brown, D L; Kulawy, Robert; Sörgel, Fritz; Heine, Henry S; Louie, Arnold.
Afiliação
  • Drusano GL; Ordway Research Institute, Albany, New York 12208, USA. Gdrusano@ordwayresearch.org
Antimicrob Agents Chemother ; 52(11): 3973-9, 2008 Nov.
Article em En | MEDLINE | ID: mdl-18725437
ABSTRACT
Sixty days of ciprofloxacin administration at 500 mg every 12 h is currently recommended for the prophylaxis of inhalational exposure to Bacillus anthracis. We examined Bacillus anthracis (Delta-Sterne strain) in our hollow-fiber infection model. We measured the ciprofloxacin concentrations achieved and the number of organisms present before heat shock (total population) and after heat shock (spore population). We fit a mathematical model to these data. Monte Carlo simulation with differing initial spore burdens (3, 5, and 6.9 log(10) CFU/ml) demonstrated that 35 days of this regimen would completely clear the spore burden in 95% of patients. Durations of 110 days did not achieve 99.9% eradication, irrespective of initial burden, because of between-patient variance in drug pharmacokinetics. Given the absence of person-to-person transmission for Bacillus anthracis, adverse drug effects with long-term ciprofloxacin administration, and the possibility of engendering resistance in bodily flora, shorter prophylaxis duration should be given consideration, along with careful monitoring of all exposed individuals.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ciprofloxacina / Antraz / Antibacterianos Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2008 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ciprofloxacina / Antraz / Antibacterianos Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2008 Tipo de documento: Article